ProCE Banner Activity

BCIRG 006: 10-Yr Follow-up of Adjuvant AC → T Compared With AC → TH and TCH for HER2+ Early BC

Slideset Download
Conference Coverage
This long-term follow-up analysis demonstrated a sustained advantage of adjuvant therapy with trastuzumab-containing regimens over the non-trastuzumab control in patients with HER2+ early breast cancer.

Released: December 18, 2015

Expiration: December 16, 2016

No longer available for credit.

Share

Provided by

Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Genentech BioOncology

Novartis Pharmaceuticals Corporation